SlideShare a Scribd company logo
Diuretics in hypertension
Guidelines
Hypertension
Leading cause of global burden of disease
At what age should screening for
hypertension begin?
Blood pressure is one of the most important screenings because
high blood pressure usually has no symptoms so it cannot be
detected without being measured
Renal
failure
(>50%)
Heart
failure
(>50%)
Stroke
(35–40%)
Myocardial
Infarction
(20–25%)
Renal
failure
(>50%)
Heart
failure
(>50%)
Stroke
(35–40%)
Myocardial
Infarction
(20–25%)
Renal
failure
(>50%)
Heart
failure
(>50%)
Stroke
(35–40%)
Myocardial
Infarction
(20–25%)
Renal
failure
(>50%)
Heart
failure
(>50%)
Stroke
(35–40%)
Myocardial
Infarction
(20–25%)
Renal
failure
(>50%)
Heart
failure
(>50%)
Stroke
(35–40%)
Myocardial
Infarction
(20–25%)
Renal
failure
(>50%)
Heart
failure
(>50%)
Stroke
(35–40%)
Myocardial
Infarction
(20–25%)
Renal
failure
(>50%)
Heart
failure
(>50%)
Stroke
(35–40%)
Myocardial
Infarction
(20–25%)
Renal
failure
(>50%)
Heart
failure
(>50%)
Stroke
(35–40%)
Myocardial
Infarction
(20–25%)
Neal et al Lancet 2000;356:1955-64
Large number of clinical trials show that getting goal BP is
associated with dramatic reduction in
What are the benefits of
achieving goal BP?
What are the first line choices available for
management?
What are the first line choices available for
management?
What are the various agents
available in India?
Diuretics Dose
Hydrochlorothiazide 6.25-12.5 mg
Chlorthalidone 6.25-12.5 mg
Indapamide 1.5-2.5 mg
Amiloride 5-10 mg
Triamterene 50-100 mg
Shah SN et al. JAPI supplement. 2013 Feb; 61 17-23
Which international guidelines
discuss diuretics?
• Joint National Committee (JNC) VIII 2014
• European Society of Hypertension (ESH) 2013
• American Heart Association (AHA) 2015
• National Institute for Health and Care Excellence (NICE) 2011
• AHA 2011: Hypertension in elderly
• American Society of Hypertension (ASH)/ International society of
Hypertension (ISH) 2014
• Taiwan Society of Cardiology 2015
• Chinese Hypertension guidelines 2015
• Korean Society of Hypertension Guidelines 2013
• Japanese Society of Hypertension Guidelines 2014
Goal BP < 140/90
9
James PA et al. JAMA. 2014 Feb 5;311(5):507-20.
JNC VIII
Hypertension with CAD: AHA/ACC/ASH
Scientific Statement 2015, Mar 30
11
Pharmacological Treatment of Hypertension in the Management of
Ischemic Heart Disease
Rosendorff C et al. J Am Soc Hypertens.2015 Mar 30. pii: S1933-1711(15)00097-2.
If a diuretic is to be initiated or changed, offer a thiazide-
like diuretic, such as Chlorthalidone (12.5 mg–25.0 mg
once daily) in preference to a conventional thiazide
diuretic such as hydrochlorothiazide
NICE guidelines National Clinical Guideline Centre - 2011
Chlorthalidone differs from HCTZ by its longer duration of
action and greater potency
Circulation. 2011;123:2434-2506.
• Clinical outcome benefits (reduction of strokes and major
cardiovascular events) have been best established with chlorthalidone,
indapamide, and hydrochlorothiazide, although evidence for the first
two of these agents has been the strongest
• Chlorthalidone has more powerful effects on blood pressure than
hydrochlorothiazide (when the same doses are compared) and
has a longer duration of action
The Journal of Clinical Hypertension. 2014; 16(1) :14-26
• "Thiazide diuretics and thiazide-like diuretics (e.g. indapamide,
chlorthalidone, etc) remain essential in the treatment of
hypertension"
• "Chlorthalidone may be the preferred thiazide-type diuretic for
hypertension in patients at high risk of cardiovascular events"
• "Chlorthalidone is at least twice as potent as HCTZ and should
be considered as the initial therapy for patients with TRH
(treatment resistant hypertension)"
Chiang C-E, et al., Journal of the Chinese Medical Association (2014), http://dx.doi.org/10.1016/j.jcma.2014.11.005
• "All five classes of antihypertensive drugs, namely CCBs,
ACE-I, ARBs, thiazide diuretics and β-blockers, were
recommended as a possible choice for initial and maintenance
antihypertensive therapy"
• "Five classes of antihypertensive drugs, including ACE-I, β-
blockers, CCB, and diuretics, were equally recommended as a
firstline treatment"
• In hypertensive patients without compelling indications, the
antihypertensive drug to be first administered should be selected from
CCBs, ARBs, ACE-I and diuretics (Recommendation grade: A,
Evidence level: I)
• Diuretics are effective for salt-sensitive hypertension, including
hypertension in the elderly
• There is evidence on their preventive effects on stroke in the Japanese
• The use of low-dose thiazide diuretics and their analogs inhibits the
appearance of metabolic adverse effects.
The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. Hypertens Res 2014; 37: 253–392.
What is the difference between thiazide and
thiazide like diuretic?
Chlorthalidone: edge over HCTZ
• Structural differences
• PK-PD advantages
• Dual mode of action
• Effective BP control
• Large clinical trials
• Meta analysis
• Guidelines recommended
• Pleiotropic effects
• Expert opinion
• Better adverse effects profile
• Survival benefits
Chlorthalidone: edge over HCTZ
• Chlorthalidone versus thiazide diuretics: distinctly different
impacts on cellular and molecular mechanisms relevant to
pathogenesis of cardiovascular disease
– Reduces epinephrine-induced platelet aggregation
– Increases angiogenesis
Hypertension. 2010;56:335-337.
Why diuretics as a first line agent?
• Have been used since the late fifties
• One of the most important group of drugs used to reduce BP, due to
efficacy and cost-effectiveness profile
• Effective in reducing BP and preventing CVD
• Major impact on reducing the risk of
 Stroke
 Heart failure
 Myocardial infarction
 Death in the population
Current choice is chlorthalidone as it has edge over HCTZ
Thank you

More Related Content

Similar to guidelines of Diuretic in hypertension 10 may.pptx

Blood pressure changes during
Blood pressure changes duringBlood pressure changes during
Blood pressure changes during
magdy elmasry
 
JNC 8 guideline to Management of Hypertension
JNC 8 guideline to Management of HypertensionJNC 8 guideline to Management of Hypertension
JNC 8 guideline to Management of Hypertension
Pranav Sopory
 
Addressing hypertension to reduce the burden of stroke 19 feb2018 (1)
Addressing hypertension to reduce  the burden of stroke 19 feb2018 (1)Addressing hypertension to reduce  the burden of stroke 19 feb2018 (1)
Addressing hypertension to reduce the burden of stroke 19 feb2018 (1)
Sudhir Kumar
 
hypertension final (4).ppt
hypertension final (4).ppthypertension final (4).ppt
hypertension final (4).ppt
GovernmentUnaniHospi
 
hypertension final (4).ppt
hypertension final (4).ppthypertension final (4).ppt
hypertension final (4).ppt
GovernmentUnaniHospi
 
Bloodpressurechangesduring
BloodpressurechangesduringBloodpressurechangesduring
Bloodpressurechangesduring
Saleh Al-Qarni
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
chiapas52
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
RDScreenTV
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
derek462361
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
ssuser04ffc5
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
raul125935
 
Hypertension final
Hypertension finalHypertension final
Hypertension final
Kennedy Nyangweso
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
Sani191640
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
shirleyjohn4
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
RezaOskui1
 
hypertension final(1).ppt
hypertension final(1).ppthypertension final(1).ppt
hypertension final(1).ppt
AdelSALLAM4
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
AnonymousFCOOcn
 
hypertension final (1).ppt
hypertension final (1).ppthypertension final (1).ppt
hypertension final (1).ppt
MominaKhan66
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
Sani191640
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
Sani191640
 

Similar to guidelines of Diuretic in hypertension 10 may.pptx (20)

Blood pressure changes during
Blood pressure changes duringBlood pressure changes during
Blood pressure changes during
 
JNC 8 guideline to Management of Hypertension
JNC 8 guideline to Management of HypertensionJNC 8 guideline to Management of Hypertension
JNC 8 guideline to Management of Hypertension
 
Addressing hypertension to reduce the burden of stroke 19 feb2018 (1)
Addressing hypertension to reduce  the burden of stroke 19 feb2018 (1)Addressing hypertension to reduce  the burden of stroke 19 feb2018 (1)
Addressing hypertension to reduce the burden of stroke 19 feb2018 (1)
 
hypertension final (4).ppt
hypertension final (4).ppthypertension final (4).ppt
hypertension final (4).ppt
 
hypertension final (4).ppt
hypertension final (4).ppthypertension final (4).ppt
hypertension final (4).ppt
 
Bloodpressurechangesduring
BloodpressurechangesduringBloodpressurechangesduring
Bloodpressurechangesduring
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
 
Hypertension final
Hypertension finalHypertension final
Hypertension final
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
 
hypertension final(1).ppt
hypertension final(1).ppthypertension final(1).ppt
hypertension final(1).ppt
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
 
hypertension final (1).ppt
hypertension final (1).ppthypertension final (1).ppt
hypertension final (1).ppt
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
 
hypertension final.ppt
hypertension final.ppthypertension final.ppt
hypertension final.ppt
 

Recently uploaded

Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
Jim Jacob Roy
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
Government Dental College & Hospital Srinagar
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
ZayedKhan38
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
Gokuldas Hospital
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
shivalingatalekar1
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Jim Jacob Roy
 
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHYMERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
DRPREETHIJAMESP
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
19various
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
LaniyaNasrink
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
Dr.pavithra Anandan
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Kosmoderma Academy Of Aesthetic Medicine
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
AksshayaRajanbabu
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
anaghabharat01
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Tina Purnat
 

Recently uploaded (20)

Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
Acute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdfAcute Gout Care & Urate Lowering Therapy .pdf
Acute Gout Care & Urate Lowering Therapy .pdf
 
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptxCLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
 
Cardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdfCardiac Assessment for B.sc Nursing Student.pdf
Cardiac Assessment for B.sc Nursing Student.pdf
 
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdfOsteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
 
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHYMERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
 
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
 
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptxREGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
vonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentationvonoprazan A novel drug for GERD presentation
vonoprazan A novel drug for GERD presentation
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
Abortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentationAbortion PG Seminar Power point presentation
Abortion PG Seminar Power point presentation
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
 
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptxshare - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
 

guidelines of Diuretic in hypertension 10 may.pptx

  • 2. Hypertension Leading cause of global burden of disease
  • 3. At what age should screening for hypertension begin? Blood pressure is one of the most important screenings because high blood pressure usually has no symptoms so it cannot be detected without being measured
  • 4. Renal failure (>50%) Heart failure (>50%) Stroke (35–40%) Myocardial Infarction (20–25%) Renal failure (>50%) Heart failure (>50%) Stroke (35–40%) Myocardial Infarction (20–25%) Renal failure (>50%) Heart failure (>50%) Stroke (35–40%) Myocardial Infarction (20–25%) Renal failure (>50%) Heart failure (>50%) Stroke (35–40%) Myocardial Infarction (20–25%) Renal failure (>50%) Heart failure (>50%) Stroke (35–40%) Myocardial Infarction (20–25%) Renal failure (>50%) Heart failure (>50%) Stroke (35–40%) Myocardial Infarction (20–25%) Renal failure (>50%) Heart failure (>50%) Stroke (35–40%) Myocardial Infarction (20–25%) Renal failure (>50%) Heart failure (>50%) Stroke (35–40%) Myocardial Infarction (20–25%) Neal et al Lancet 2000;356:1955-64 Large number of clinical trials show that getting goal BP is associated with dramatic reduction in What are the benefits of achieving goal BP?
  • 5. What are the first line choices available for management?
  • 6. What are the first line choices available for management?
  • 7. What are the various agents available in India? Diuretics Dose Hydrochlorothiazide 6.25-12.5 mg Chlorthalidone 6.25-12.5 mg Indapamide 1.5-2.5 mg Amiloride 5-10 mg Triamterene 50-100 mg Shah SN et al. JAPI supplement. 2013 Feb; 61 17-23
  • 8. Which international guidelines discuss diuretics? • Joint National Committee (JNC) VIII 2014 • European Society of Hypertension (ESH) 2013 • American Heart Association (AHA) 2015 • National Institute for Health and Care Excellence (NICE) 2011 • AHA 2011: Hypertension in elderly • American Society of Hypertension (ASH)/ International society of Hypertension (ISH) 2014 • Taiwan Society of Cardiology 2015 • Chinese Hypertension guidelines 2015 • Korean Society of Hypertension Guidelines 2013 • Japanese Society of Hypertension Guidelines 2014
  • 9. Goal BP < 140/90 9 James PA et al. JAMA. 2014 Feb 5;311(5):507-20. JNC VIII
  • 10.
  • 11. Hypertension with CAD: AHA/ACC/ASH Scientific Statement 2015, Mar 30 11 Pharmacological Treatment of Hypertension in the Management of Ischemic Heart Disease Rosendorff C et al. J Am Soc Hypertens.2015 Mar 30. pii: S1933-1711(15)00097-2.
  • 12. If a diuretic is to be initiated or changed, offer a thiazide- like diuretic, such as Chlorthalidone (12.5 mg–25.0 mg once daily) in preference to a conventional thiazide diuretic such as hydrochlorothiazide NICE guidelines National Clinical Guideline Centre - 2011
  • 13. Chlorthalidone differs from HCTZ by its longer duration of action and greater potency Circulation. 2011;123:2434-2506.
  • 14. • Clinical outcome benefits (reduction of strokes and major cardiovascular events) have been best established with chlorthalidone, indapamide, and hydrochlorothiazide, although evidence for the first two of these agents has been the strongest • Chlorthalidone has more powerful effects on blood pressure than hydrochlorothiazide (when the same doses are compared) and has a longer duration of action The Journal of Clinical Hypertension. 2014; 16(1) :14-26
  • 15. • "Thiazide diuretics and thiazide-like diuretics (e.g. indapamide, chlorthalidone, etc) remain essential in the treatment of hypertension" • "Chlorthalidone may be the preferred thiazide-type diuretic for hypertension in patients at high risk of cardiovascular events" • "Chlorthalidone is at least twice as potent as HCTZ and should be considered as the initial therapy for patients with TRH (treatment resistant hypertension)" Chiang C-E, et al., Journal of the Chinese Medical Association (2014), http://dx.doi.org/10.1016/j.jcma.2014.11.005
  • 16. • "All five classes of antihypertensive drugs, namely CCBs, ACE-I, ARBs, thiazide diuretics and β-blockers, were recommended as a possible choice for initial and maintenance antihypertensive therapy"
  • 17. • "Five classes of antihypertensive drugs, including ACE-I, β- blockers, CCB, and diuretics, were equally recommended as a firstline treatment"
  • 18. • In hypertensive patients without compelling indications, the antihypertensive drug to be first administered should be selected from CCBs, ARBs, ACE-I and diuretics (Recommendation grade: A, Evidence level: I) • Diuretics are effective for salt-sensitive hypertension, including hypertension in the elderly • There is evidence on their preventive effects on stroke in the Japanese • The use of low-dose thiazide diuretics and their analogs inhibits the appearance of metabolic adverse effects. The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. Hypertens Res 2014; 37: 253–392.
  • 19. What is the difference between thiazide and thiazide like diuretic? Chlorthalidone: edge over HCTZ • Structural differences • PK-PD advantages • Dual mode of action • Effective BP control • Large clinical trials • Meta analysis • Guidelines recommended • Pleiotropic effects • Expert opinion • Better adverse effects profile • Survival benefits
  • 21. • Chlorthalidone versus thiazide diuretics: distinctly different impacts on cellular and molecular mechanisms relevant to pathogenesis of cardiovascular disease – Reduces epinephrine-induced platelet aggregation – Increases angiogenesis Hypertension. 2010;56:335-337.
  • 22. Why diuretics as a first line agent? • Have been used since the late fifties • One of the most important group of drugs used to reduce BP, due to efficacy and cost-effectiveness profile • Effective in reducing BP and preventing CVD • Major impact on reducing the risk of  Stroke  Heart failure  Myocardial infarction  Death in the population Current choice is chlorthalidone as it has edge over HCTZ

Editor's Notes

  1. Effective treatment of hypertension significantly reduces morbidity and mortality when patients achieve BP Goal In a large number of clinical trials, antihypertensive therapy and getting patients to BP goal has been associated with dramatic reductions in a number of CV endpoints, for example stroke reductions of 35–40 % myocardial infarction (MI), reductions of 20–25 % and heart failure (HF), reductions of > 50 % This clearly demonstrates the importance of Getting to goal!!! The reductions reported are relative and should be placed in the correct context with regard to frequency of observation. More information on risk reduction can be found in Chobanian et al. 2003 References Chobanian etal. JAMA 2003;289(19):2560-72. Hansson et al. Lancet 1998;351:1755–62 Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64.